linjc16/ctgov huggingface dataset:
Exercise Capacity in Diseases and Health

Study Overview
=================
Brief Summary
-----------------
Exercise capacity is a key factor to evaluate and treat patients in different diseases (e.g. ischemic heart disease, chronic obstructive pulmonary disease, cystic fibrosis). The best way to measure exercise capacity is to perform a cardiopulmonary exercise testing. Normal/reference values in health and disease relate to specific population and subpopulations. The population in Israel is unique in its diversity. Objectives: Data collection of exercise capacity assessment in health and illness in the northern of Israel for future local database. Population: 500 Patients evaluated routinely in the exercise lab (pediatric cardiology institute) and healthy volunteers evaluated as controls. Study design: Prospective observational study. Participants will answer a health related questioner, undergo a physical examination, perform a cardiopulmonary exercise test on a treadmill or a cycle ergometer.

Detailed Description
-----------------
Exercise capacity is a key factor to evaluate and treat patients in different diseases (e.g. ischemic heart disease, chronic obstructive pulmonary disease, cystic fibrosis). The best way to measure exercise capacity is to perform a cardiopulmonary exercise testing. Normal/reference values in health and disease relate to specific population and subpopulations. The population in Israel is unique in its diversity. Objectives: Data collection of exercise capacity assessment in health and illness in the northern of Israel for future local database. Population: 500 Patients evaluated routinely in the exercise lab (pediatric cardiology institute) and healthy volunteers evaluated as controls. Study design: Prospective observational study. Participants will answer a health related questioner, undergo a physical examination, perform a cardiopulmonary exercise test on a treadmill or a cycle ergometer .

Official Title
-----------------
Exercise Capacity in Diseases and Health

Conditions
-----------------
Exercise Capacity

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Ability to complete full exercise evaluation (including cardiopulmonary exercise testing). Exclusion Criteria: Acute illness on visit day. for healthy volunteers: chronic disease or use of medications. Professional athletes.

Ages Eligible for Study
-----------------
Minimum Age: 6 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| VO2 (oxygen consumption) |  | 30 minutes |
A Study of BNC210 in Elderly Patients With Agitation

Study Overview
=================
Brief Summary
-----------------
This is a Phase II randomised, double-blind, placebo-controlled study assessing the effects of BNC210 on agitation in hospitalised elderly patients as measured by the Pittsburgh Agitation Scale (PAS). Safety and tolerability of BNC210 will also be assessed. The secondary objectives of the study include evaluation of the effects of BNC210 on global function in patients with agitation as assessed by the Clinical Global Impression Scale (CGI-S/I). Participants will receive 5 days of blinded treatment followed by 2 days of follow up.

Official Title
-----------------
A Phase II Randomised, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of BNC210 in Hospitalised Elderly Patients With Agitation

Conditions
-----------------
Agitation in the Elderly

Intervention / Treatment
-----------------
* Drug: BNC210
* Drug: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Key Inclusion Criteria: Male or female elderly patient admitted to hospital and under the care of a specialist Geriatrician Determined to have agitation requiring intervention in addition to standard of care behavioural management, as assessed by the Investigator or delegate, after at least 24 hours following admission to hospital. Key Exclusion Criteria: Severe Alzheimer's Dementia (stage 7) as assessed by the Functional Assessment Staging Test (FAST). Diagnosed with Severe Parkinson's Disease. Premorbid psychotic illness as assessed by the Investigator. Evidence of severe organ dysfunction Confirmed metastatic malignancy.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: BNC210<br>Administered orally b.i.d. for 5 days. | Drug: BNC210<br>* BNC210 300 mg b.i.d<br>|
| Placebo Comparator: Placebo<br>Administered orally b.i.d. for 5 days. | Drug: Placebo<br>* Placebo b.i.d.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Absolute change in agitation, as measured by the Pittsburgh Agitation Scale (PAS). |  | 5 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Absolute change in global function, as measured by the Clinical Global Impression Scale - Severity and Improvement (CGI-S/I) |  | 5 days | 
| Proportion of participants reaching the Non-Agitated state |  | 5 days | 
| Time to first reach a Non-Agitated state. |  | 5 days |
Prophylaxis of Venous Thromboembolism in Advanced Lung Cancer

Study Overview
=================
Brief Summary
-----------------
To compare the efficacy and safety of prophylaxis of venous thromboembolism by Nadroparin during hospitalization to long-term usage in patients with advanced lung cancer treated by chemotherapy and/or radiotherapy.

Detailed Description
-----------------
This is a prospective, multi-center, randomized and controlled study. Advanced lung cancer patients without venous thromboembolism(VTE) are included. The selected patients were randomized into A and B groups. Group A: Nadroparin given during hospitalization, 0.4mL, subcutaneously, qid; Group B: Nadroparin given by long-term, 0.4mL, subcutaneously, qid. The incidence of VTE , the risks of bleeding and overall survival in two groups of patients are studied at different time points.

Official Title
-----------------
Phase Ⅲ Study of Prophylaxis of Venous Thromboembolism in Advanced Lung Cancer by Nadroparin

Conditions
-----------------
Lung Cancer

Intervention / Treatment
-----------------
* Drug: Nadroparin, long term
* Drug: Nadroparin: short-term


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Stage Ⅲ B and Ⅳ non-small cell lung cancer patients and inoperable small cell lung cancer patients Performance status score ≤ 2 Chest CT with measurable lesions Exclusion Criteria: Examination revealed any part of venous thromboembolism Chemotherapy regimens containing bevacizumab or Endostar Severe coagulopathy Active bleeding within two weeks

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Long term prophylaxis<br>Nadroparin, 0.4mL, subcutaneously, qid, given by long-term | Drug: Nadroparin, long term<br> <br> |
| Active Comparator: Short-term prophylaxis<br>Nadroparin, 0.4mL, subcutaneously, qid, given during hospitalization | Drug: Nadroparin: short-term<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence of venous thromboembolism |  | 12 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence of bleeding |  | During 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Nadroparin, venous thromboembolism prophylaxis
Learning Curve of External Pop Out as a New Technique for Lower Uterine Segment Support

Study Overview
=================
Brief Summary
-----------------
Cesarean section represent the most significant operative intervention in all of obstetrics, its development and application have saved lives of countless mothers and infants. the frequency with which its carried out continues to rise and has in many hospitals and health regions reached rates in excess of 30%(

Official Title
-----------------
Delivery of Fetal Head During Cesarean Section; Acceptability and Learning Curve of External Pop Out as a New Technique for Lower Uterine Segment Support; A Cross- Sectional Study

Conditions
-----------------
Cesarean Section Complications

Intervention / Treatment
-----------------
* Procedure: External Pop-out


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Singleton term pregnancy Cephalic presentation Women who will accept to participate in the study Exclusion Criteria: Non-cephalic presentation Congenital fetal anomalies Multiple pregnancy Preterm caesarean < 37 weeks Cases with marked adhesions obscuring the lower uterine segment thickness
Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: External Pop-out|The original techniques of fetal head extraction entail the introduction of the obstetricians' hands or other instruments into the LUS. This puts the LUS at risk of damage and incision extensions with its consequences of increased blood loss, increased operative time,infection adhesions and blood transfusion.To the available, the generated good quality evidence bases practice in CS is anticipated to decrease such morbidities|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The number of cesarean sections that are required for the obstetrician to reach turning point . | the number needed to achieve a good learning curve | 1 month |
Acupressure for COVID-19 Related Quality of Life and Stress

Study Overview
=================
Brief Summary
-----------------
This study is being conducted to evaluate the efficacy of acupressure in promoting health and well-being among healthcare workers during the COVID-19 pandemic. The investigators hypothesize that providing participants with a remote and standardized self-acupressure training program will improve HRQOL and the perception of stress. In the event that the study demonstrates acupressure to be safe and effective for this indication, the training could be scaled up and deployed at low-cost nationally and internationally.

Official Title
-----------------
Randomized Controlled Trial of Acupressure for Health-Related Quality of Life and Perception of Stress Among Health Care Providers During the COVID-19 Pandemic

Conditions
-----------------
Quality of Life, Stress

Intervention / Treatment
-----------------
* Behavioral: Self-acupressure


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All adult patients (18 years of age and over) who are health care providers according to self-report will be eligible for participation with the exception of subjects meeting exclusion criteria as below. Exclusion Criteria: Exclusion criteria includes subjects who are physically unable to participate (e.g., from severe arthritis) or cognitively unable to participate (e.g., from dementia) will be excluded. Patients unable to provide their own informed consent will be excluded. Patients under the age of 18 years will be excluded. Pregnant women will be excluded. Patients who have previous training in acupressure will be excluded.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Self-acupressure<br> | Behavioral: Self-acupressure<br>* Self-acupressure<br>|
| No Intervention: Control<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Health Related Quality of Life | SF-12v2 | 8 weeks | 
| Perception of stress | Perceived Stress Scale | 8 weeks |
Challenges Faced By Neurophysiotherapist While Consultation Through Tele-rehabilitation

Study Overview
=================
Brief Summary
-----------------
Being the most important stakeholder of such a vulnerable population, the neuro physiotherapist faced a lot of difficulties while consulting and assessing patients with neurological impairments. Up to our knowledge and search history, this is the first-ever study conducted by us which list out the challenges faced by neuro physiotherapist while teleconsultation mode among Indian population.

Detailed Description
-----------------
During the ongoing Covid-19 pandemic many Neurophysiotherapist opted for telerehabilitation to provide rehabilitation to the patients. This study aims to find out challenges faced by Neurophysiotherapist (NeuroPT) for consultation through telerehabilitation within Maharashtra provenance. A total of 103 NeuroPT within Maharashtra provenance were contacted through this online survey. A brief, structured and validated questionnaire was constructed as there is no gold standard questionnaire developed to obtain responses from the neuro physiotherapists opting for telerehabilitation mode for their consultations with their clients. The questionnaire was sent by What's app and email to gather basic information to describe the various challenges in consultation through telerehabilitation.

Official Title
-----------------
Challenges Faced By Neurophysiotherapist While Consultation Through Telerehabilitation Within Maharashtra State- A Cross-Sectional Study

Conditions
-----------------
Stroke, Parkinson' s Disease, Neurological Impairments, Tele-rehabilitation

Intervention / Treatment
-----------------
* Other: Opinions about tele-rehabilitation for consulting a clients with neurological impairments


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria:- A cross-sectional study was carried out to obtain the responses from the neuro physiotherapist practicing within Maharashtra provenance. Exclusion Criteria: Neurophysiotherapist practicing outside of Maharashtra provenance

Ages Eligible for Study
-----------------
Minimum Age: 25 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Opinions about tele-rehabilitation for consulting a clients with neurological impairments|Opinions about telerehabilitation for consultation purpose|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Consultation Questionnaire | A structured Questionnaire for Assessing a Challenges while consulting their clients through Tele-rehabilitation mode | 1 Week |
Vitamin D Replacement in Nonalcoholic Fatty Liver Disease

Study Overview
=================
Brief Summary
-----------------
Vitamin D deficiency is very common in patients with fatty liver disease as evidenced by our observations in the Metabolic Liver Clinic and that reported by others. We also observed that patients with more severe fatty liver disease had lower Vitamin D concentrations. Others have shown that replacing Vitamin D in patients with cirrhosis is effective and even patients with Vitamin D replete status have lowering of Vitamin D over time if not supplemented. One of the measures of liver injury in NAFLD is the plasma concentration of ALT and we will use this to follow patients as is currently done as standard of care. All patients in the Metabolic Liver Clinic are being routinely screened for Vitamin D deficiency as standard of care and treatment is being started with oral supplementation, but there are not standardized protocols to determine success of therapy. We hypothesize that patients with NAFLD with low Vitamin D levels will respond appropriately to Vitamin D supplementation for 6 months.

Official Title
-----------------
Vitamin D Replacement in Nonalcoholic Fatty Liver Disease

Conditions
-----------------
Nonalcoholic Fatty Liver

Intervention / Treatment
-----------------
* Dietary Supplement: Vitamind D


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adults of age 18 or greater Diagnosis of fatty liver disease with a low Vitamin D level (< 30 ng/dl) in the past 6 months Able to give consent Exclusion Criteria: Those currently receiving Vitamin D supplementation

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patients with Vitamin D level of <30ng/dL<br>This is a cohort of patients with fatty liver disease and also have low levels of vitamin D | Dietary Supplement: Vitamind D<br>* Patients will be given an over the counter vitamin D supplement of 2000 units of D3 daily for 6 months<br>|
| Patients with Vitamin D level of >30ng/dL<br>This is a cohort of patients with fatty liver disease and have normal levels of vitamin D | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in vitamin D levels | Change in plasma vitamin D levels from baseline to 6 months | Baseline and 6 months | 
| Change in liver and renal function | Change in hepatic function panel and renal function panel from baseline to 6 months | Baseline and 6 months | 
| Change in body composition data | Change in blood pressure, waist circumference, BIA and CT scan if performed clinically | Baseline and 6 months | 
| Chang in lipid profile | Change in HDL, LDL, and TG from baseline to 6 months | Baseline and 6 months | 
| Change in insulin resistance | Change in insulin resistance from baseline to 6 months | Basline and 6 months |
Role of Anterior Segment Optical Coherence Tomography in Infectious Keratitis

Study Overview
=================
Brief Summary
-----------------
To evaluate the role of anterior segment optical coherence tomography in follow up of infectious keratitis and assessment of response to treatment.

Detailed Description
-----------------
50 patients with proven infectious keratitis clinically will be included in the study. The following will be performed for all patients in initial visit and follow up: Slit lamp examination and photography. Visual acuity assessment. Anterior segment optical coherence tomography. The central corneal thickness (CCT) (extracted from pachymetry map), Minimal corneal thickness (MCT) (extracted from pachymetry map) Corneal thickness at the site of the lesion (CTL) (extracted from pachymetry map or the sum of STL+ CETL) Stromal thickness at the center of the lesion (STL) stromal lesion (extracted from stromal map) Corneal epithelial thickness over the stromal lesion (CETL) at the center of the lesion (extracted from epithelial map)

Official Title
-----------------
Role of Anterior Segment Optical Coherence Tomography in Staging and Evaluation of Treatment Response in Infectious Keratitis

Conditions
-----------------
Infective Keratitis

Intervention / Treatment
-----------------
* Other: Optical coherence tomography


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Any case with infectious keratitis (any age) either received medical treatment or not, attending to our department will be included in the study. Exclusion Criteria: Cases with healed infectious keratitis. Cases presented from the start with severe corneal affection and melting.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| infective keratitis<br>50 cases with infectious keratitis (any age) either received medical treatment or not, attending to our department will be included in the study. | Other: Optical coherence tomography<br>* Anterior segment optical coherence tomography examination of corneas with infective keratitis<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| criteria of lesion on optical coherence tomography | Localiztion, depth of infiltration area in microns | 1 month | 
| width of lesion on optical coherence tomography | width of infiltration in microns | 1 month |